Clinical Trial Update: Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 trial compares rituximab to continued corticosteroid treatment in idiopathic nephrotic syndrome, including minimal change disease and focal segmental …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Idiopathic Nephrotic Syndrome
• Minimal Change Disease

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Idiopathic Nephrotic Syndrome, Minimal Change Disease | Phase 3 | Status: UNKNOWN